Latest news with #BrianSchall
Malaysian Reserve
16 hours ago
- Business
- Malaysian Reserve
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, July 15, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow, Inc. ('Harrow' or 'the Company') (NASDAQ: HROW) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Harrow announced its financial results for Q1 2025 on May 8, 2025. The Company reported revenues that missed consensus estimates and adjusted EBITDA of –$1.9 million. Based on this news, shares of Harrow fell by more than 4%. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335info@
Business Wire
17 hours ago
- Business
- Business Wire
BRBR Investors Have Opportunity to Join BellRing Brands, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BellRing Brands, Inc. ('BellRing' or 'the Company') (NYSE: BRBR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. BellRing revealed during its Q2 earnings call on May 6, 2026, that its Q3 sales growth would slow to 'low-single-digits' as some customers choose to 'optimize' inventories by reducing their 'weeks of supply on hand.' Based on this news, shares of BellRing fell by almost 19% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
18 hours ago
- Business
- Globe and Mail
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biohaven Ltd. ('Biohaven' or 'the Company') (NYSE: BHVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2023 and May 14, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before September 12, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Biohaven overstated the regulatory prospects of its drug candidate troriluzole as a treatment for SCA. The Company also overstated the efficacy of BHV-7000 as a treatment for bipolar disorder. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Biohaven, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Business Wire
18 hours ago
- Business
- Business Wire
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biohaven Ltd. ('Biohaven' or 'the Company') (NYSE: BHVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2023 and May 14, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before September 12, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Biohaven overstated the regulatory prospects of its drug candidate troriluzole as a treatment for SCA. The Company also overstated the efficacy of BHV-7000 as a treatment for bipolar disorder. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Biohaven, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
18 hours ago
- Business
- Business Wire
KBR Investors Have Opportunity to Join KBR, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of KBR, Inc. ('KBR' or 'the Company') (NYSE: KBR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The Department of Defense announced on June 18, 2025, that it had canceled a multibillion-dollar contract with HomeSafe Alliance ('HAS'), a KBR joint venture, for 'cause due to HSA's demonstrated inability to fulfill their obligations and deliver high quality moves to Service members.' Based on this news, shares of KBR fell by 7.3% on June 20, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
